Vietnam

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection
  • July 11th, 2014
  • A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

» Read More...
Featured Research »
Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

Health & Medicine »
Vietnamese Human Genome Completed

Vietnamese Human Genome Completed

Scientists in Vietnam have completed the sequencing and analysis of a Vietnamese human genome.

Academia »
Vietnamese School Children ‘Years Ahead’ Of Indian Pupils, Study

Vietnamese School Children ‘Years Ahead’ Of Indian Pupils, Study

A new study has found that even the most disadvantaged children in Vietnam are educationally years ahead of their peers in India.

Tech & Pharma »
Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

The Phase III trial, which enrolled more than 10,000 children in Asia, showed that vaccination led to a 56 percent reduction in dengue cases.

Editorials »
Bridging The ASEAN Research Gap

Bridging The ASEAN Research Gap

Research and innovation in ASEAN has not kept pace with economic growth the region has enjoyed, writes Crispin Maslog.